Clinical Trial Update: Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy [Phase 1]

View source ↗

Summary

Phase 1 interaction study assessing the effect of CYP3A inhibitors on ibrutinib exposure in patients with chronic lymphocytic leukemia; the study is complete.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: B-Cell Chronic Lymphocytic Leukemia | Phase 1 | Status: COMPLETED